3D Cell Culture Market is valued at USD 1.1 Billion in 2021 and expected to reach USD 3.22 Billion by 2028 with the a CAGR of 16.5% over theforecastperiod
Overview-
3D cell culture technique generates normal cell morphology, proliferation, differentiation andmigration. It offersan ideal environment for cell culture analytical studies, which involve assessment of multistage disease models with the help of 3D cellular modeling. It is a controlled simulated environment outside of a living organism, where cells are allowed to grow and migrate by interacting within their habitat.
Industry Insights-
• 3D Cell Culture Market was valued at USD 1.1 Billion in 2021
• It is expected to reach USD 3.22 Billion by 2028
• A CAGR of 16.5% is anticipated over the forecast period
Key Players-
Some of the key players for global 3D cell culture market are
• Thermo Fisher Scientific
• Becton Dickinson and Company
• Corning Incorporated
• Sigma-Aldrich Corporation
• 3D Biomatrix
• 3D Biotek
• Reinnervate
• InSphero AG
• Global Cell Solutions
• Lonza Group
• VWR International
• Nano3D Biosciences
• Tecan
• Merck KGaA
• PromoCell GmbH
• Greiner Bio One International GmbH
• Avantor Performance Materials LLC
• REPROCELL Inc.
• MIMETAS BV
• others
Segmentation Analysis-
By Technology-
• Extracellular Matrices Or Scaffolds
• Bioreactors
• Gels
• Scaffold-Free Platforms
• Microchips
By Application-
• Drug Discovery
• Tissue Engineering
• Clinical Applications
• Stem Cell Biology
By End-User-
• Research Laboratories And Institutes
• Biotechnology And Pharmaceutical Industries
• Hospitals And Diagnostic Centers
• Others
By Regional & Country Analysis
North America
• U.S.
• Canada
Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe
Asia-Pacific
• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC
Latin America
• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America
MiddleEastand Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA
The outbreak of COVID-19 has resulted in a surge of interest in cell culture as a platform for developing novel vaccines for the treatment of the disease. 3D cell culture market players have taken initiatives in this direction, with Captivate Bio launching its portfolio of cell culture tools to assist in the fight against COVID-19 and other emerging diseases in the United States in January 2021. This has had a noticeable effect on the growth of the market.
Market Drivers-
3D cell culture is becoming imperative in the healthcare sector
3D cell culture is becoming imperative in the healthcare sector due to its significant range of applications in cancer research, in vitro environment, and regenerative medicine. The necessary help from 3D cell culture to strengthen the understanding of tissue maturation and organization, organogenesis, and cell differentiation has increased its utility. It has also replaced animal prototypes in clinical testing and experiments, as these cells look similar to cells in vivo.
Rising number of cancer cases around the world to increase the demand
The 3D cell culture market is expected to grow at a rapid rate due to factors such as increasing R&D activities in drug discovery, rising prevalence of cancer, and increasing demand for personalized medicines. Additionally, the increasing number of collaborations between research institutes and biotechnology companies is also driving the market. Furthermore, with the development of advanced technology, such as 3D cell culture and microfluidics, the 3D cell culture market is likely to witness significant growth in the upcoming years.
Opportunities-
Emergence of new products in 3D cell culture
The launch of Thermo Fisher Scientific's new Gibco Human Plasma-like Medium (HPLM) in March 2021 is expected to drive the growth of the 3D cell culture market. HPLM is one of the first types of cell culture medium
that replicates the metabolic profile of human plasma, providing researchers with a realistic view of cell growth within the human body.
Recent Developments-
• In June 2022, Evonik debuted the cQrex portfolio, a range of cell culture ingredients designed to improve the efficacy and productivity of bioprocesses used to manufacture vaccines, monoclonal antibodies, therapeutic cells, and viral vectors.
• In February of 2022, CellulaREvolution was able to secure GBP 1.75 million in funding to expedite the introduction of its groundbreaking continuous cell culture technology.